Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow experienced a drop of 0.2%, and the technology-dominated Nasdaq saw a decrease of 0.24%. Shares of the drugmaker have appreciated by 8.03% over the course of the past month, outperforming the Medical sector's loss of 0.56%, and the S&P 500's gain of 0.94%.The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. The company is expected to report EPS of $5.05, up 26.88% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $3.16 billion, indicating a 8.65% increase compared to the same quarter of the previous year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $18.4 per share and a revenue of $11.98 billion, signifying shifts of +4280.95% and +8.69%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.41% upward. Currently, Vertex Pharmaceuticals is carrying a Zacks Rank of #3 (Hold). Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 24.99. This signifies a premium in comparison to the average Forward P/E of 18.93 for its industry. The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 106, placing it within the top 43% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks